nodes	percent_of_prediction	percent_of_DWPC	metapath
Salmeterol—CYP3A7—Sorafenib—thyroid cancer	0.151	0.226	CbGbCtD
Salmeterol—CYP3A7-CYP3A51P—Sorafenib—thyroid cancer	0.151	0.226	CbGbCtD
Salmeterol—CYP3A5—Sorafenib—thyroid cancer	0.114	0.169	CbGbCtD
Salmeterol—CYP2C8—Sorafenib—thyroid cancer	0.109	0.163	CbGbCtD
Salmeterol—CYP3A4—Vandetanib—thyroid cancer	0.0735	0.11	CbGbCtD
Salmeterol—CYP3A4—Sorafenib—thyroid cancer	0.0443	0.0661	CbGbCtD
Salmeterol—CYP3A4—Doxorubicin—thyroid cancer	0.0269	0.0401	CbGbCtD
Salmeterol—Malnutrition—Vandetanib—thyroid cancer	0.00178	0.0054	CcSEcCtD
Salmeterol—Muscle spasms—Vandetanib—thyroid cancer	0.00171	0.00519	CcSEcCtD
Salmeterol—Tremor—Vandetanib—thyroid cancer	0.00167	0.00506	CcSEcCtD
Salmeterol—Abdominal discomfort—Sorafenib—thyroid cancer	0.00165	0.00501	CcSEcCtD
Salmeterol—Oral candidiasis—Epirubicin—thyroid cancer	0.0016	0.00485	CcSEcCtD
Salmeterol—Keratitis—Epirubicin—thyroid cancer	0.00156	0.00475	CcSEcCtD
Salmeterol—Cough—Vandetanib—thyroid cancer	0.00155	0.00471	CcSEcCtD
Salmeterol—Pneumonia—Sorafenib—thyroid cancer	0.00154	0.00469	CcSEcCtD
Salmeterol—Hypertension—Vandetanib—thyroid cancer	0.00154	0.00466	CcSEcCtD
Salmeterol—Infestation NOS—Sorafenib—thyroid cancer	0.00154	0.00466	CcSEcCtD
Salmeterol—Infestation—Sorafenib—thyroid cancer	0.00154	0.00466	CcSEcCtD
Salmeterol—Chest pain—Vandetanib—thyroid cancer	0.00151	0.00459	CcSEcCtD
Salmeterol—Arthralgia—Vandetanib—thyroid cancer	0.00151	0.00459	CcSEcCtD
Salmeterol—Anxiety—Vandetanib—thyroid cancer	0.00151	0.00458	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.0015	0.00456	CcSEcCtD
Salmeterol—Dry mouth—Vandetanib—thyroid cancer	0.00148	0.00449	CcSEcCtD
Salmeterol—Oral candidiasis—Doxorubicin—thyroid cancer	0.00148	0.00448	CcSEcCtD
Salmeterol—Oedema—Vandetanib—thyroid cancer	0.00145	0.0044	CcSEcCtD
Salmeterol—Epistaxis—Sorafenib—thyroid cancer	0.00145	0.00439	CcSEcCtD
Salmeterol—Keratitis—Doxorubicin—thyroid cancer	0.00145	0.00439	CcSEcCtD
Salmeterol—Infection—Vandetanib—thyroid cancer	0.00144	0.00438	CcSEcCtD
Salmeterol—Nervous system disorder—Vandetanib—thyroid cancer	0.00142	0.00432	CcSEcCtD
Salmeterol—Skin disorder—Vandetanib—thyroid cancer	0.00141	0.00428	CcSEcCtD
Salmeterol—Laryngitis—Epirubicin—thyroid cancer	0.00141	0.00427	CcSEcCtD
Salmeterol—Dermatitis atopic—Epirubicin—thyroid cancer	0.00137	0.00416	CcSEcCtD
Salmeterol—Connective tissue disorder—Sorafenib—thyroid cancer	0.00135	0.00411	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00132	0.00401	CcSEcCtD
Salmeterol—Insomnia—Vandetanib—thyroid cancer	0.00131	0.00398	CcSEcCtD
Salmeterol—Paraesthesia—Vandetanib—thyroid cancer	0.0013	0.00396	CcSEcCtD
Salmeterol—Laryngitis—Doxorubicin—thyroid cancer	0.0013	0.00395	CcSEcCtD
Salmeterol—Dyspnoea—Vandetanib—thyroid cancer	0.00129	0.00393	CcSEcCtD
Salmeterol—Cardiac disorder—Sorafenib—thyroid cancer	0.00128	0.00388	CcSEcCtD
Salmeterol—Dyspepsia—Vandetanib—thyroid cancer	0.00128	0.00388	CcSEcCtD
Salmeterol—Dermatitis atopic—Doxorubicin—thyroid cancer	0.00127	0.00385	CcSEcCtD
Salmeterol—Fatigue—Vandetanib—thyroid cancer	0.00125	0.0038	CcSEcCtD
Salmeterol—Immune system disorder—Sorafenib—thyroid cancer	0.00125	0.00378	CcSEcCtD
Salmeterol—Mediastinal disorder—Sorafenib—thyroid cancer	0.00124	0.00377	CcSEcCtD
Salmeterol—Constipation—Vandetanib—thyroid cancer	0.00124	0.00377	CcSEcCtD
Salmeterol—Pain—Vandetanib—thyroid cancer	0.00124	0.00377	CcSEcCtD
Salmeterol—Dysphonia—Epirubicin—thyroid cancer	0.00123	0.00374	CcSEcCtD
Salmeterol—Arrhythmia—Sorafenib—thyroid cancer	0.00123	0.00374	CcSEcCtD
Salmeterol—Mental disorder—Sorafenib—thyroid cancer	0.00121	0.00366	CcSEcCtD
Salmeterol—Malnutrition—Sorafenib—thyroid cancer	0.0012	0.00364	CcSEcCtD
Salmeterol—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00119	0.0036	CcSEcCtD
Salmeterol—Vasodilation procedure—Epirubicin—thyroid cancer	0.00115	0.0035	CcSEcCtD
Salmeterol—Vasodilation—Epirubicin—thyroid cancer	0.00115	0.0035	CcSEcCtD
Salmeterol—Muscle spasms—Sorafenib—thyroid cancer	0.00115	0.0035	CcSEcCtD
Salmeterol—Abdominal pain—Vandetanib—thyroid cancer	0.00115	0.00348	CcSEcCtD
Salmeterol—Body temperature increased—Vandetanib—thyroid cancer	0.00115	0.00348	CcSEcCtD
Salmeterol—Dysphonia—Doxorubicin—thyroid cancer	0.00114	0.00346	CcSEcCtD
Salmeterol—Viral infection—Epirubicin—thyroid cancer	0.00112	0.00341	CcSEcCtD
Salmeterol—Angioedema—Sorafenib—thyroid cancer	0.0011	0.00333	CcSEcCtD
Salmeterol—Vasodilation—Doxorubicin—thyroid cancer	0.00107	0.00324	CcSEcCtD
Salmeterol—Vasodilation procedure—Doxorubicin—thyroid cancer	0.00107	0.00324	CcSEcCtD
Salmeterol—Bone pain—Epirubicin—thyroid cancer	0.00106	0.00321	CcSEcCtD
Salmeterol—Cough—Sorafenib—thyroid cancer	0.00105	0.00318	CcSEcCtD
Salmeterol—Inflammation—Epirubicin—thyroid cancer	0.00105	0.00317	CcSEcCtD
Salmeterol—Asthenia—Vandetanib—thyroid cancer	0.00104	0.00316	CcSEcCtD
Salmeterol—Viral infection—Doxorubicin—thyroid cancer	0.00104	0.00315	CcSEcCtD
Salmeterol—Hypertension—Sorafenib—thyroid cancer	0.00104	0.00314	CcSEcCtD
Salmeterol—Musculoskeletal pain—Epirubicin—thyroid cancer	0.00103	0.00312	CcSEcCtD
Salmeterol—Neck pain—Epirubicin—thyroid cancer	0.00103	0.00312	CcSEcCtD
Salmeterol—Arthralgia—Sorafenib—thyroid cancer	0.00102	0.0031	CcSEcCtD
Salmeterol—Myalgia—Sorafenib—thyroid cancer	0.00102	0.0031	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00101	0.00308	CcSEcCtD
Salmeterol—Ventricular tachycardia—Epirubicin—thyroid cancer	0.00101	0.00308	CcSEcCtD
Salmeterol—Dermatitis contact—Epirubicin—thyroid cancer	0.001	0.00304	CcSEcCtD
Salmeterol—Dry mouth—Sorafenib—thyroid cancer	0.000999	0.00303	CcSEcCtD
Salmeterol—Diarrhoea—Vandetanib—thyroid cancer	0.000993	0.00301	CcSEcCtD
Salmeterol—Bone pain—Doxorubicin—thyroid cancer	0.00098	0.00297	CcSEcCtD
Salmeterol—Anaphylactic shock—Sorafenib—thyroid cancer	0.000979	0.00297	CcSEcCtD
Salmeterol—Infection—Sorafenib—thyroid cancer	0.000973	0.00295	CcSEcCtD
Salmeterol—Candida infection—Epirubicin—thyroid cancer	0.000969	0.00294	CcSEcCtD
Salmeterol—Inflammation—Doxorubicin—thyroid cancer	0.000968	0.00294	CcSEcCtD
Salmeterol—Nervous system disorder—Sorafenib—thyroid cancer	0.00096	0.00291	CcSEcCtD
Salmeterol—Dizziness—Vandetanib—thyroid cancer	0.00096	0.00291	CcSEcCtD
Salmeterol—Skin disorder—Sorafenib—thyroid cancer	0.000951	0.00289	CcSEcCtD
Salmeterol—Musculoskeletal pain—Doxorubicin—thyroid cancer	0.00095	0.00288	CcSEcCtD
Salmeterol—Neck pain—Doxorubicin—thyroid cancer	0.00095	0.00288	CcSEcCtD
Salmeterol—Ventricular tachycardia—Doxorubicin—thyroid cancer	0.000939	0.00285	CcSEcCtD
Salmeterol—Cramps of lower extremities—Epirubicin—thyroid cancer	0.000932	0.00283	CcSEcCtD
Salmeterol—Dermatitis contact—Doxorubicin—thyroid cancer	0.000928	0.00281	CcSEcCtD
Salmeterol—Vomiting—Vandetanib—thyroid cancer	0.000923	0.0028	CcSEcCtD
Salmeterol—Rash—Vandetanib—thyroid cancer	0.000915	0.00278	CcSEcCtD
Salmeterol—Dermatitis—Vandetanib—thyroid cancer	0.000915	0.00277	CcSEcCtD
Salmeterol—Headache—Vandetanib—thyroid cancer	0.00091	0.00276	CcSEcCtD
Salmeterol—Candida infection—Doxorubicin—thyroid cancer	0.000896	0.00272	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.000892	0.00271	CcSEcCtD
Salmeterol—Dyspnoea—Sorafenib—thyroid cancer	0.000873	0.00265	CcSEcCtD
Salmeterol—Nausea—Vandetanib—thyroid cancer	0.000862	0.00262	CcSEcCtD
Salmeterol—Cramps of lower extremities—Doxorubicin—thyroid cancer	0.000862	0.00262	CcSEcCtD
Salmeterol—Dyspepsia—Sorafenib—thyroid cancer	0.000862	0.00262	CcSEcCtD
Salmeterol—Fatigue—Sorafenib—thyroid cancer	0.000844	0.00256	CcSEcCtD
Salmeterol—Pain—Sorafenib—thyroid cancer	0.000837	0.00254	CcSEcCtD
Salmeterol—Constipation—Sorafenib—thyroid cancer	0.000837	0.00254	CcSEcCtD
Salmeterol—Eczema—Epirubicin—thyroid cancer	0.000819	0.00249	CcSEcCtD
Salmeterol—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000801	0.00243	CcSEcCtD
Salmeterol—Urticaria—Sorafenib—thyroid cancer	0.000778	0.00236	CcSEcCtD
Salmeterol—Body temperature increased—Sorafenib—thyroid cancer	0.000774	0.00235	CcSEcCtD
Salmeterol—Abdominal pain—Sorafenib—thyroid cancer	0.000774	0.00235	CcSEcCtD
Salmeterol—Eczema—Doxorubicin—thyroid cancer	0.000758	0.0023	CcSEcCtD
Salmeterol—Pain in extremity—Epirubicin—thyroid cancer	0.000736	0.00223	CcSEcCtD
Salmeterol—Migraine—Epirubicin—thyroid cancer	0.000725	0.0022	CcSEcCtD
Salmeterol—Hypersensitivity—Sorafenib—thyroid cancer	0.000722	0.00219	CcSEcCtD
Salmeterol—Asthenia—Sorafenib—thyroid cancer	0.000703	0.00213	CcSEcCtD
Salmeterol—Pain in extremity—Doxorubicin—thyroid cancer	0.000681	0.00207	CcSEcCtD
Salmeterol—Abdominal pain upper—Epirubicin—thyroid cancer	0.000673	0.00204	CcSEcCtD
Salmeterol—Migraine—Doxorubicin—thyroid cancer	0.000671	0.00203	CcSEcCtD
Salmeterol—Diarrhoea—Sorafenib—thyroid cancer	0.00067	0.00203	CcSEcCtD
Salmeterol—Nasopharyngitis—Epirubicin—thyroid cancer	0.000659	0.002	CcSEcCtD
Salmeterol—Dizziness—Sorafenib—thyroid cancer	0.000648	0.00196	CcSEcCtD
Salmeterol—Asthma—Epirubicin—thyroid cancer	0.000636	0.00193	CcSEcCtD
Salmeterol—Influenza—Epirubicin—thyroid cancer	0.000636	0.00193	CcSEcCtD
Salmeterol—Vomiting—Sorafenib—thyroid cancer	0.000623	0.00189	CcSEcCtD
Salmeterol—Abdominal pain upper—Doxorubicin—thyroid cancer	0.000622	0.00189	CcSEcCtD
Salmeterol—Rash—Sorafenib—thyroid cancer	0.000618	0.00187	CcSEcCtD
Salmeterol—Dermatitis—Sorafenib—thyroid cancer	0.000617	0.00187	CcSEcCtD
Salmeterol—Headache—Sorafenib—thyroid cancer	0.000614	0.00186	CcSEcCtD
Salmeterol—Bronchitis—Epirubicin—thyroid cancer	0.000612	0.00186	CcSEcCtD
Salmeterol—Nasopharyngitis—Doxorubicin—thyroid cancer	0.000609	0.00185	CcSEcCtD
Salmeterol—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.000592	0.00179	CcSEcCtD
Salmeterol—Asthma—Doxorubicin—thyroid cancer	0.000589	0.00179	CcSEcCtD
Salmeterol—Influenza—Doxorubicin—thyroid cancer	0.000589	0.00179	CcSEcCtD
Salmeterol—Nausea—Sorafenib—thyroid cancer	0.000582	0.00176	CcSEcCtD
Salmeterol—Hyperglycaemia—Epirubicin—thyroid cancer	0.000574	0.00174	CcSEcCtD
Salmeterol—Pneumonia—Epirubicin—thyroid cancer	0.000571	0.00173	CcSEcCtD
Salmeterol—Infestation NOS—Epirubicin—thyroid cancer	0.000567	0.00172	CcSEcCtD
Salmeterol—Infestation—Epirubicin—thyroid cancer	0.000567	0.00172	CcSEcCtD
Salmeterol—Bronchitis—Doxorubicin—thyroid cancer	0.000566	0.00172	CcSEcCtD
Salmeterol—Conjunctivitis—Epirubicin—thyroid cancer	0.000552	0.00167	CcSEcCtD
Salmeterol—Urinary tract infection—Epirubicin—thyroid cancer	0.000552	0.00167	CcSEcCtD
Salmeterol—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.000547	0.00166	CcSEcCtD
Salmeterol—Epistaxis—Epirubicin—thyroid cancer	0.000535	0.00162	CcSEcCtD
Salmeterol—Sinusitis—Epirubicin—thyroid cancer	0.000532	0.00162	CcSEcCtD
Salmeterol—Hyperglycaemia—Doxorubicin—thyroid cancer	0.000531	0.00161	CcSEcCtD
Salmeterol—Pneumonia—Doxorubicin—thyroid cancer	0.000528	0.0016	CcSEcCtD
Salmeterol—Infestation—Doxorubicin—thyroid cancer	0.000525	0.00159	CcSEcCtD
Salmeterol—Infestation NOS—Doxorubicin—thyroid cancer	0.000525	0.00159	CcSEcCtD
Salmeterol—Rhinitis—Epirubicin—thyroid cancer	0.000511	0.00155	CcSEcCtD
Salmeterol—Conjunctivitis—Doxorubicin—thyroid cancer	0.00051	0.00155	CcSEcCtD
Salmeterol—Urinary tract infection—Doxorubicin—thyroid cancer	0.00051	0.00155	CcSEcCtD
Salmeterol—Pharyngitis—Epirubicin—thyroid cancer	0.000506	0.00153	CcSEcCtD
Salmeterol—Connective tissue disorder—Epirubicin—thyroid cancer	0.000501	0.00152	CcSEcCtD
Salmeterol—Epistaxis—Doxorubicin—thyroid cancer	0.000495	0.0015	CcSEcCtD
Salmeterol—Sinusitis—Doxorubicin—thyroid cancer	0.000493	0.00149	CcSEcCtD
Salmeterol—Cardiac disorder—Epirubicin—thyroid cancer	0.000473	0.00143	CcSEcCtD
Salmeterol—Rhinitis—Doxorubicin—thyroid cancer	0.000473	0.00143	CcSEcCtD
Salmeterol—Pharyngitis—Doxorubicin—thyroid cancer	0.000468	0.00142	CcSEcCtD
Salmeterol—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000463	0.00141	CcSEcCtD
Salmeterol—Immune system disorder—Epirubicin—thyroid cancer	0.00046	0.0014	CcSEcCtD
Salmeterol—Mediastinal disorder—Epirubicin—thyroid cancer	0.000459	0.00139	CcSEcCtD
Salmeterol—Arrhythmia—Epirubicin—thyroid cancer	0.000455	0.00138	CcSEcCtD
Salmeterol—Mental disorder—Epirubicin—thyroid cancer	0.000446	0.00135	CcSEcCtD
Salmeterol—Malnutrition—Epirubicin—thyroid cancer	0.000443	0.00135	CcSEcCtD
Salmeterol—Cardiac disorder—Doxorubicin—thyroid cancer	0.000437	0.00133	CcSEcCtD
Salmeterol—Tension—Epirubicin—thyroid cancer	0.000435	0.00132	CcSEcCtD
Salmeterol—Nervousness—Epirubicin—thyroid cancer	0.000431	0.00131	CcSEcCtD
Salmeterol—Back pain—Epirubicin—thyroid cancer	0.000429	0.0013	CcSEcCtD
Salmeterol—Muscle spasms—Epirubicin—thyroid cancer	0.000426	0.00129	CcSEcCtD
Salmeterol—Immune system disorder—Doxorubicin—thyroid cancer	0.000426	0.00129	CcSEcCtD
Salmeterol—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000425	0.00129	CcSEcCtD
Salmeterol—Arrhythmia—Doxorubicin—thyroid cancer	0.000421	0.00128	CcSEcCtD
Salmeterol—Mental disorder—Doxorubicin—thyroid cancer	0.000413	0.00125	CcSEcCtD
Salmeterol—Ill-defined disorder—Epirubicin—thyroid cancer	0.000411	0.00125	CcSEcCtD
Salmeterol—Malnutrition—Doxorubicin—thyroid cancer	0.00041	0.00124	CcSEcCtD
Salmeterol—Agitation—Epirubicin—thyroid cancer	0.000408	0.00124	CcSEcCtD
Salmeterol—Tension—Doxorubicin—thyroid cancer	0.000403	0.00122	CcSEcCtD
Salmeterol—Malaise—Epirubicin—thyroid cancer	0.0004	0.00121	CcSEcCtD
Salmeterol—Nervousness—Doxorubicin—thyroid cancer	0.000399	0.00121	CcSEcCtD
Salmeterol—Back pain—Doxorubicin—thyroid cancer	0.000397	0.0012	CcSEcCtD
Salmeterol—Muscle spasms—Doxorubicin—thyroid cancer	0.000395	0.0012	CcSEcCtD
Salmeterol—Palpitations—Epirubicin—thyroid cancer	0.000392	0.00119	CcSEcCtD
Salmeterol—Cough—Epirubicin—thyroid cancer	0.000387	0.00117	CcSEcCtD
Salmeterol—Hypertension—Epirubicin—thyroid cancer	0.000383	0.00116	CcSEcCtD
Salmeterol—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000381	0.00116	CcSEcCtD
Salmeterol—Chest pain—Epirubicin—thyroid cancer	0.000378	0.00115	CcSEcCtD
Salmeterol—Arthralgia—Epirubicin—thyroid cancer	0.000378	0.00115	CcSEcCtD
Salmeterol—Myalgia—Epirubicin—thyroid cancer	0.000378	0.00115	CcSEcCtD
Salmeterol—Agitation—Doxorubicin—thyroid cancer	0.000377	0.00114	CcSEcCtD
Salmeterol—Anxiety—Epirubicin—thyroid cancer	0.000376	0.00114	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000375	0.00114	CcSEcCtD
Salmeterol—Discomfort—Epirubicin—thyroid cancer	0.000373	0.00113	CcSEcCtD
Salmeterol—Malaise—Doxorubicin—thyroid cancer	0.00037	0.00112	CcSEcCtD
Salmeterol—Dry mouth—Epirubicin—thyroid cancer	0.000369	0.00112	CcSEcCtD
Salmeterol—Palpitations—Doxorubicin—thyroid cancer	0.000363	0.0011	CcSEcCtD
Salmeterol—Oedema—Epirubicin—thyroid cancer	0.000362	0.0011	CcSEcCtD
Salmeterol—Anaphylactic shock—Epirubicin—thyroid cancer	0.000362	0.0011	CcSEcCtD
Salmeterol—Infection—Epirubicin—thyroid cancer	0.00036	0.00109	CcSEcCtD
Salmeterol—Cough—Doxorubicin—thyroid cancer	0.000358	0.00109	CcSEcCtD
Salmeterol—Nervous system disorder—Epirubicin—thyroid cancer	0.000355	0.00108	CcSEcCtD
Salmeterol—Hypertension—Doxorubicin—thyroid cancer	0.000354	0.00107	CcSEcCtD
Salmeterol—Tachycardia—Epirubicin—thyroid cancer	0.000353	0.00107	CcSEcCtD
Salmeterol—Skin disorder—Epirubicin—thyroid cancer	0.000352	0.00107	CcSEcCtD
Salmeterol—Chest pain—Doxorubicin—thyroid cancer	0.000349	0.00106	CcSEcCtD
Salmeterol—Myalgia—Doxorubicin—thyroid cancer	0.000349	0.00106	CcSEcCtD
Salmeterol—Arthralgia—Doxorubicin—thyroid cancer	0.000349	0.00106	CcSEcCtD
Salmeterol—Anxiety—Doxorubicin—thyroid cancer	0.000348	0.00106	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000347	0.00105	CcSEcCtD
Salmeterol—Discomfort—Doxorubicin—thyroid cancer	0.000345	0.00105	CcSEcCtD
Salmeterol—Dry mouth—Doxorubicin—thyroid cancer	0.000342	0.00104	CcSEcCtD
Salmeterol—Oedema—Doxorubicin—thyroid cancer	0.000335	0.00102	CcSEcCtD
Salmeterol—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000335	0.00102	CcSEcCtD
Salmeterol—Infection—Doxorubicin—thyroid cancer	0.000333	0.00101	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.00033	0.001	CcSEcCtD
Salmeterol—Nervous system disorder—Doxorubicin—thyroid cancer	0.000328	0.000996	CcSEcCtD
Salmeterol—Insomnia—Epirubicin—thyroid cancer	0.000327	0.000993	CcSEcCtD
Salmeterol—Tachycardia—Doxorubicin—thyroid cancer	0.000327	0.000992	CcSEcCtD
Salmeterol—Skin disorder—Doxorubicin—thyroid cancer	0.000325	0.000987	CcSEcCtD
Salmeterol—Paraesthesia—Epirubicin—thyroid cancer	0.000325	0.000986	CcSEcCtD
Salmeterol—Dyspnoea—Epirubicin—thyroid cancer	0.000323	0.000979	CcSEcCtD
Salmeterol—Dyspepsia—Epirubicin—thyroid cancer	0.000319	0.000967	CcSEcCtD
Salmeterol—Fatigue—Epirubicin—thyroid cancer	0.000312	0.000947	CcSEcCtD
Salmeterol—Constipation—Epirubicin—thyroid cancer	0.00031	0.000939	CcSEcCtD
Salmeterol—Pain—Epirubicin—thyroid cancer	0.00031	0.000939	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000305	0.000926	CcSEcCtD
Salmeterol—Insomnia—Doxorubicin—thyroid cancer	0.000303	0.000919	CcSEcCtD
Salmeterol—Paraesthesia—Doxorubicin—thyroid cancer	0.000301	0.000912	CcSEcCtD
Salmeterol—Dyspnoea—Doxorubicin—thyroid cancer	0.000299	0.000906	CcSEcCtD
Salmeterol—Feeling abnormal—Epirubicin—thyroid cancer	0.000298	0.000905	CcSEcCtD
Salmeterol—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000296	0.000898	CcSEcCtD
Salmeterol—Dyspepsia—Doxorubicin—thyroid cancer	0.000295	0.000894	CcSEcCtD
Salmeterol—Fatigue—Doxorubicin—thyroid cancer	0.000289	0.000876	CcSEcCtD
Salmeterol—Urticaria—Epirubicin—thyroid cancer	0.000288	0.000872	CcSEcCtD
Salmeterol—Pain—Doxorubicin—thyroid cancer	0.000286	0.000869	CcSEcCtD
Salmeterol—Constipation—Doxorubicin—thyroid cancer	0.000286	0.000869	CcSEcCtD
Salmeterol—Abdominal pain—Epirubicin—thyroid cancer	0.000286	0.000868	CcSEcCtD
Salmeterol—Body temperature increased—Epirubicin—thyroid cancer	0.000286	0.000868	CcSEcCtD
Salmeterol—Feeling abnormal—Doxorubicin—thyroid cancer	0.000276	0.000837	CcSEcCtD
Salmeterol—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000274	0.000831	CcSEcCtD
Salmeterol—Hypersensitivity—Epirubicin—thyroid cancer	0.000267	0.000809	CcSEcCtD
Salmeterol—Urticaria—Doxorubicin—thyroid cancer	0.000266	0.000807	CcSEcCtD
Salmeterol—Abdominal pain—Doxorubicin—thyroid cancer	0.000265	0.000803	CcSEcCtD
Salmeterol—Body temperature increased—Doxorubicin—thyroid cancer	0.000265	0.000803	CcSEcCtD
Salmeterol—Asthenia—Epirubicin—thyroid cancer	0.00026	0.000788	CcSEcCtD
Salmeterol—Diarrhoea—Epirubicin—thyroid cancer	0.000248	0.000751	CcSEcCtD
Salmeterol—Hypersensitivity—Doxorubicin—thyroid cancer	0.000247	0.000749	CcSEcCtD
Salmeterol—Asthenia—Doxorubicin—thyroid cancer	0.00024	0.000729	CcSEcCtD
Salmeterol—Dizziness—Epirubicin—thyroid cancer	0.000239	0.000726	CcSEcCtD
Salmeterol—Vomiting—Epirubicin—thyroid cancer	0.00023	0.000698	CcSEcCtD
Salmeterol—Diarrhoea—Doxorubicin—thyroid cancer	0.000229	0.000695	CcSEcCtD
Salmeterol—Rash—Epirubicin—thyroid cancer	0.000228	0.000692	CcSEcCtD
Salmeterol—Dermatitis—Epirubicin—thyroid cancer	0.000228	0.000692	CcSEcCtD
Salmeterol—Headache—Epirubicin—thyroid cancer	0.000227	0.000688	CcSEcCtD
Salmeterol—Dizziness—Doxorubicin—thyroid cancer	0.000221	0.000672	CcSEcCtD
Salmeterol—Nausea—Epirubicin—thyroid cancer	0.000215	0.000652	CcSEcCtD
Salmeterol—Vomiting—Doxorubicin—thyroid cancer	0.000213	0.000646	CcSEcCtD
Salmeterol—Rash—Doxorubicin—thyroid cancer	0.000211	0.000641	CcSEcCtD
Salmeterol—Dermatitis—Doxorubicin—thyroid cancer	0.000211	0.00064	CcSEcCtD
Salmeterol—Headache—Doxorubicin—thyroid cancer	0.00021	0.000637	CcSEcCtD
Salmeterol—Nausea—Doxorubicin—thyroid cancer	0.000199	0.000604	CcSEcCtD
